Joos G F, Pauwels R A, Van der Straeten M E
Department of Respiratory Diseases, University Hospital, Ghent, Belgium.
Drugs. 1989;37 Suppl 1:109-12; discussion 127-36. doi: 10.2165/00003495-198900371-00019.
In a double-blind, crossover study we have investigated the effect of nedocromil sodium on neurokinin A (NKA)-induced bronchoconstriction in asthmatics. 12 patients with mild asthma inhaled either nedocromil sodium 4mg or placebo, on 2 separate days, as 2 puffs from a metered-dose aerosol 30 minutes before challenge with NKA. On the placebo treatment day, NKA produced a concentration-dependent decrease in basal specific airway conductance (sGaw) and forced expiratory volume in 1 second (FEV1). The inhalation of nedocromil sodium 4mg inhibited the decrease in both sGaw and FEV1. The maximal percentage decrease in sGaw on the nedocromil sodium day was 27.0 +/- 5.2 (vs placebo, 53.3 +/- 5.4; p less than 0.05) and the maximal percentage decrease in FEV1 5.5 +/- 1.4 (vs placebo, 12.4 +/- 2.3; p less than 0.05). We conclude that nedocromil sodium protects against NKA-induced bronchoconstriction in asthmatics.
在一项双盲交叉研究中，我们调查了奈多罗米钠对哮喘患者中神经激肽A（NKA）诱发的支气管收缩的影响。12名轻度哮喘患者在2个不同的日子里，于用NKA激发前30分钟，从定量气雾剂中吸入4毫克奈多罗米钠或安慰剂，每次2喷。在安慰剂治疗日，NKA使基础比气道传导率（sGaw）和第1秒用力呼气量（FEV1）呈浓度依赖性降低。吸入4毫克奈多罗米钠可抑制sGaw和FEV1的降低。在奈多罗米钠治疗日，sGaw的最大百分比降低为27.0±5.2（安慰剂组为53.3±5.4；p<0.05），FEV1的最大百分比降低为5.5±1.4（安慰剂组为12.4±2.3；p<0.05）。我们得出结论，奈多罗米钠可预防哮喘患者中NKA诱发的支气管收缩。
